|
Day 1 - Friday 27 October 2017
Registration: 2.30pm - 3.30pm
|
|
Session 1
|
Time
|
Title: Biology and genetic of breast cancer
|
Speaker
|
| |
3.30pm – 4pm
|
OPENING SPEECH
|
Dr Ussama AL Homsi Dr Salha Al Bader
|
| |
4pm - 4.30pm
|
Molecular basis of breast cancer and key biological pathway
|
Dr. Tracy L. Stockley
|
| |
4.30pm – 5pm
|
Reporting and pathological staging of breast cancer
|
Dr. Imaad Bin Mujeeb
|
| |
5pm - 5.30pm
|
Hereditary breast cancer- genetic counselling and testing
|
Dr. Reem Al-Sulaiman
|
| |
5.30pm – 6pm
|
Management of genetic mutation carriers
|
Dr. Salha Bujassoum
|
|
Break
|
6pm - 6.30pm
|
Coffee break
|
|
|
Session 2
|
Title : Imaging session
|
| |
6.30pm – 7pm
|
Updates on breast cancer national screening
|
Dr. Shaikha Abushaikha
|
| |
7pm - 7.30pm
|
Role of PET- CT in the staging of breast cancer
|
Dr. Lajos Szabados
|
| |
7.30pm – 8pm
|
Controversies in surveillance for low risk DCIS and those who survived beyond 5 years
|
Dr Iman Abass
|
|
Break
|
8pm
|
Dinner
|
|
|
Day 2 - Saturday 28 October 2017
Registration: 8am – 9am
|
|
Session 3
|
Title: Loco-regional therapy
|
| |
9am - 9.30am
|
Prevention and management of seroma in post-surgical breast cancer patients, a comprehensive review of literature
|
Ms. Nahrida Nazir Band (CNS)
|
| |
9.30am - 10am
|
Choices of breast re-construction post mastectomy
|
Dr. Habib AL-Basti
|
| |
10am - 10.30 am
|
The role and the latissimus dorsi myocutaneous flap in breast reconstruction after breast mastectomy’
|
Dr. Talal AL-Hitmi
|
|
Break
|
10.30am - 10.45am
|
Coffee break
|
|
| |
10.45am - 11.15am
|
That chest wall radiotherapy prior to mastectomy
|
Dr. Hissa Al-Abdulla
|
| |
11.15am - 11.45pm
|
Is regional nodal radiotherapy required to all early stage node positive breast cancer?
|
Dr. Palmira Caparrotti
|
| |
11. 45pm - 12.15pm
|
Role of clinical nurse specialist for breast cancer
|
Dr.Terri Mc Ewan
|
|
Break
|
12.15pm - 1.15pm
|
Lunch break and prayer
|
|
|
Session 4
|
Title: Systemic management of breast cancer
|
| |
1.15pm - 1.45pm
|
In neoadjuvant chemotherapy choice should be based on more TNM stage vs biological subtype
|
Dr. Nuhad Ibrahim
|
|
1. 45pm - 2.15pm
|
Immunotherapy/TNBC
|
Dr. David Warr
|
|
2.15pm - 2.45pm
|
Treat HER early: Updates on HER2 positive Neoadjuvant BC
|
Dr. Mark Verrill
|
|
2. 45pm - 3.15pm
|
Duration of/choice of adjuvant endocrine therapy
|
Dr. Mufid Elmistiri
|
|
3. 15pm - 3.45pm
|
( Break and prayer )
|
|
| 3. 45pm - 4.15pm |
That OFS + hormonal treatment should be standard of care in young patients with high-risk HR+ve breast cancer
|
Dr. Nuhad Ibrahim
|
| |
4.15pm - 4.45pm |
Update in hormone treatment for metastatic breast cancer
|
Dr. Francois Calaud
|
| |
4.45pm - 5pm
|
Closing remark
|
Dr. Salha Bujassoum
|
Workshop
- Clinical Breast Examination (Friday) by Breast Cancer Team / Dr. Mohammed Elias 3:00PM – 4:00PM
- Meet the expert : Case Discussion (Saturday after the session) by Roche Company
Dr. Hind El Malk, Dr. Cicy Mary Jacob and Dr. Ashraf Awad 5PM – 5:45 PM.
